Evaluación de la eficacia del tratamiento adyuvante en cáncer colorrectal estadio II, Instituto Oncológico Nacional Dr. Juan Tanca Marengo 2006 - 2010.
Fecha
2012
Autores
Título de la revista
ISSN de la revista
Título del volumen
Editor
Universidad de Guayaquil. Facultad de Ciencias Médicas. Escuela de Graduados
Resumen
El cáncer colorrectal es un grave problema de salud pública a nivel mundial. Representa
la tercera causa por neoplasia y la segunda causa de muerte luego del cáncer de pulmón
en varones y del cáncer de mama en mujeres. Existen varios factores de riesgos que
influyen en el pronóstico de esta enfermedad. La estadificación del tumor es el factor
más importante para evaluar el tiempo libre de enfermedad y la sobrevida global. La
cirugía es el tratamiento principal en estadios I – III, sin embargo, la posibilidad de
recurrencia es alta. Por tanto, la utilidad de la quimioterapia adyuvante es erradicar las
micrometástasis y mejorar la sobrevida del paciente. En estadio II, la quimioterapia
adyuvante es controversial, debido a que estos pacientes tienen un buen pronóstico,
excepto aquellos con factores desfavorables. El objetivo del estudio propuesto fué
conocer la tasa de sobrevida global y libre de enfermedad en los pacientes con cáncer
colorrectal en estadio II, y determinar el protocolo de quimioterapia más utilizado en el
Instituto Oncológico Nacional SOLCA “Dr. Juan Tanca Marengo”. Para esto se utilizó
una metodología de tipo descriptivo, diseño no experimental, longitudinal -
retrospectivo en el período de enero 2006 a diciembre 2010. Se analizaron mediante el
sistema SPSS, las características clínico - patológicas de 101 pacientes con
adenocarcinoma de colon que recibieron quimioterapia adyuvante, siendo el protocolo
FOLFOX el más utilizado. La sobrevida global media estimada a 3 años fue del 75%.
Colorectal cancer is a serious public health problem worldwide. Represents the third leading cause of malignancy and the second leading cause of death after lung cancer in men and breast cancer in women. There are several risk factors that influence the prognosis of this disease. Tumor staging is the most important factor to evaluate the disease free and overall survival. Surgery is the primary treatment in stages I - III, however, the possibility of recurrence is high. Therefore, the usefulness of adjuvant chemotherapy is to eradicate micrometastases and improve patient survival. In stage II, adjuvant chemotherapy is controversial, because these patients have a good prognosis, except those with unfavorable factors. The objective of the proposed study was to determine the rate of overall survival and disease-free patients with stage II colorectal cancer, and determine the most widely used chemotherapy protocol in the National Cancer Institute SOLCA "Dr. Juan Tanca Marengo. "For this we used a descriptive methodology, non-experimental, longitudinal - retrospective from January 2006 to December 2010. Were analyzed using the SPSS system, the clinico - pathological of 101 patients with colon adenocarcinoma who received adjuvant chemotherapy, FOLFOX protocol being used the most. The average estimated overall survival at 3 years was 75%.
Colorectal cancer is a serious public health problem worldwide. Represents the third leading cause of malignancy and the second leading cause of death after lung cancer in men and breast cancer in women. There are several risk factors that influence the prognosis of this disease. Tumor staging is the most important factor to evaluate the disease free and overall survival. Surgery is the primary treatment in stages I - III, however, the possibility of recurrence is high. Therefore, the usefulness of adjuvant chemotherapy is to eradicate micrometastases and improve patient survival. In stage II, adjuvant chemotherapy is controversial, because these patients have a good prognosis, except those with unfavorable factors. The objective of the proposed study was to determine the rate of overall survival and disease-free patients with stage II colorectal cancer, and determine the most widely used chemotherapy protocol in the National Cancer Institute SOLCA "Dr. Juan Tanca Marengo. "For this we used a descriptive methodology, non-experimental, longitudinal - retrospective from January 2006 to December 2010. Were analyzed using the SPSS system, the clinico - pathological of 101 patients with colon adenocarcinoma who received adjuvant chemotherapy, FOLFOX protocol being used the most. The average estimated overall survival at 3 years was 75%.
Descripción
Palabras clave
Neoplasias del colon, Neoplasias del recto, Quimioterapia, Evaluación, Epidemiología descriptiva, Hospital SOLCA de Guayaquil, Cantón Guayaquil, Ecuador